IPSEF - IPO Update: Lantern Pharma Readies $25 Million IPO
Quick Take
Lantern Pharma (LTRN) intends to raise $25 million in gross proceeds from an IPO of its common stock, per an amended registration statement.
The company is advancing a pipeline of drug treatment candidates identified by its proprietary RADR platform.
LTRN believes it can better stratify patient populations for improved trial results for previously failed Phase 3 trials drug candidates.
Perhaps it can, but other biopharmas with a similar plan have yet to show success, so I'll pass on the IPO.
Company & Technology
Dallas, Texas-based Lantern was founded to use